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Abstract 
Psoriasis is a systemic inflammatory skin disease affecting up to 3% of the 
population. Skin lesions are symmetric erythematous papules and plaques with 
sharp demarcation covered with silvery white scales in scalp, elbows, knees, 
fingers and sacral areas. Metabolic diseases such as obesity and diabetes are 
more common in psoriatic patients. Strong evidence suggests T lymphocyte 
based immunogenesis and an increased amount of proinflammatory cytokines 
including IL-1, IL-6, IL-8 and TNF- alpha were detected in psoriatic plaques. 
We report a 51-year-old male patient with a history of psoriasis for 30 years 
scheduled for coronary artery bypass grafting surgery and discuss the anesthetic 
implications in such patients. 
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Introduction 
Psoriasis, a skin disease is a dilemma if surgery 
and perioperative care is going to be provided. Here we 
discuss a man with psoriasis undergoing CABG. 
 
Case Report 
A 51-year-old male patient with a history of 
psoriasis for 30 years was referred to a tertiary 
university hospital with complaint of chest pain and 
was scheduled for coronary artery bypass grafting 
surgery. He had a one-year history of diabetes and a 7 
years history of hypertension and a 15 pack-year 
history of smoking. The psoriatic lesions were on the 
limbs and the posterior part of the trunk with spotty 
bleeding in some parts due to removal of silvery scales 
in various involved areas (Figures 1-3). The patient did 
not receive any medications regarding the psoriasis 
disease. Head and neck examination for assessment of 
difficult airway was normal. The standard lab test 
values were within the normal range. The angiographic 
study showed coronary artery involvement. 
Transthoracic echocardiography showed an ejection 
fraction of 35 to 40%. Carotid vessel angiography was 
normal. A lateral neck X-Ray was done to rule out the 
involvement of cervical spine. No evidence of psoriatic 
arthritis was detected during physical examination. 
Dermatology consult was done and due to lack of 
lesions in surgical site, there seemed to be no 
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complications regarding this issue. The prophylactic 
dose of antibiotic and the stress dose of corticosteroids 
were administered one hour prior to surgery. All 
necessary precautions were in place to minimize the 
chance of skin injuries to prevent the Koebner 
phenomenon. The patient was monitored properly and 
the anesthesia was administered according to the 
current protocols for cardiac surgery anesthesia. The 
perioperative period was uneventful and the patient 
was transferred to cardiac ICU where he was extubated 
24 hours later. He was discharged 10 days later with no 
exacerbation of psoriasis disease. 
Discussion 
Psoriasis is a systemic immune-mediated skin 
disease with prevalence of up to 3 percent (1). It affects 
125 million people worldwide and afflicts men and 
women equally (2). The disease is more prevalent 
among people living in high altitudes and cold climates 
and less prevalent among people who have greater sun 
exposure. Psoriasis has two peaks of age distribution 
the earlier one is between 15 to 30 years of age which 
is associated with more severe disease and the later 
peak is between 50 to 60 years of age (3). The early 
onset disease with severe progression is accompanied 
by human leukocyte antigen (HLA) factors (1, 4). The 
lifetime risk for developing psoriasis is 4% in a patient 
with no familial history, 14-28% if one parent is 
afflicted and 41-65% if both parents are afflicted. 
Penetration of psoriasis is higher if the carrier is the 
father (1, 3, 4). Skin lesions in psoriasis are caused by 
hyperproliferation of keratinocytes without 
differentiation and epidermal hyperplasia, which is 
triggered by leukocyte infiltration (2). Classically 
lesions are symmetric erythematous papules and 
plaques with sharp demarcation covered with silvery 
white scales in scalp, elbows, knees, fingers and sacral 
areas. In some patients, it afflicts the entire integument 
including palms, soles fingernails and oral mucosa. 
The disease has some variant forms including chronic 
plaque, gut Tate, pustular and erythroderma.  
Koebner phenomenon also known as 
isomorphic response is formation of new lesions at the 
site of trauma that occurs one to two weeks after the 
injury in all - or – none pattern. Several factor such as 
emotional stress, certain medications and infections 
can trigger psoriatic lesions (1, 3). Other components 
such as contact dermatitis, eczema, irritant dermatitis, 
herpes zoster, impetigo contagiosa and sunburns can 
contribute to activation of the disease process. Upper 
respiratory tract infections, streptococcal infections 
and mycotic infections are among prevalent infectious 
causes triggering the disease. Many different 
 
Figure 1. Psoriatic lesions on the torso. 
 
Figure 2. Psoriatic lesions on the upper limb. 
 
Figure 3. Psoriatic lesions on the lower limb. 
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medications can aggravate the disease including 
systemic corticosteroids, beta-adrenergic antagonists, 
lithium, non–steroidal anti-inflammatory drugs and 
anti–malarial. Strong evidence suggests T lymphocyte 
based immunogenesis and an increased amount of 
proinflammatory cytokines including IL-1, IL-6, IL-8 
and TNF-alpha were detected in psoriatic plaques (1, 
4).  
 
Comorbidities: Twenty-five percent of patients 
demonstrate inflammatory seronegative spondylo-
arthropathy with tenderness swelling and stiffness of 
joints and surrounding tendons and ligaments. 
Enthesitis (nail involvement) is frequently seen 
especially in patients with distal interphalangeal joint 
involvement. Patients afflicted with psoriasis are prone 
to autoimmune diseases and dysregulation of TNF-
alpha and are more likely to develop Crohn's disease. 
Psoriasis is also more prevalent in families with 
multiple sclerosis (3). Like other inflammatory 
diseases such as rheumatoid arthritis and systemic 
lupus erythematosus, psoriasis is accompanied by 
increased atherosclerosis and risk of coronary artery 
disease (2). The relative risks of myocardial infarction 
and stroke are increased in psoriatic patients especially 
in younger patients with more severe disease which can 
cause a 3 to 4 years decrease in life expectancy (2, 3, 
5). Metabolic diseases such as obesity and diabetes are 
more common in psoriatic patients. The up-regulation 
of pro-inflammatory mediators influence the adipocyte 
homoeostasis that leads to disturbed adipokine profile. 
Meanwhile inflammation associated with psoriasis 
increases insulin resistance leading to endothelial 
dysfunction, atherosclerosis and coronary events (1, 3-
5). Psoriatic patients also have a higher prevalence of 
abdominal obesity and hypertriglyceridemia (3). 
Successful treatment with methotrexate can deduct the 
rate of myocardial infarction in psoriatic patients. 
TNF-alpha inhibitors decrease insulin resistance and 
have a higher protective effect against the development 
of diabetes and cardiovascular disease (1, 2, 4). Some 
studies show psoriatic patients have an increased risk 
for developing lymphoma. Near to 60% of psoriatic 
patients have mood disorders such as depression and a 
large proportion of these patients may actively commit 
suicide (3). 
 
Treatment: topical treatments include vitamin D3 
analogues, corticosteroids and phototherapy including 
UVB and PUVA. Systemic treatments consist of 
conventional drugs such as methotrexate, retinoid 
agents and cyclosporine A and new drugs including 
humanized monoclonal antibodies which inhibit T-cell 
activation such as Efalizumab (1). 
 
Anesthetic considerations: holding to account the 
systemic inflammatory nature of the disease detailed 
medical history should be obtained and trill physical 
examination should be performed. It should include the 
patient's age, the duration of the disease and any co-
morbidities, current functional status and current 
medications including steroids. 
Obesity is a known characteristic of psoriatic 
patients that increases the risk of surgical site 
infections and deep vein thrombosis. Psoriasis is 
associated with metabolic syndrome risk factors such 
as high levels of triglycerides and fasting glucose, low 
levels of high-density lipoprotein cholesterol, elevated 
blood pressure and abdominal obesity. Psoriasis is an 
independent risk factor for myocardial infarction 
therefore preoperative assessment should include trill 
evaluation of cardiac status. Cervical spine 
involvement should be assessed and lateral neck X-
Ray should be obtained. Assessment of skin 
involvement in surgical site is imperative. Surgical 
incisions should not involve psoriatic lesions due to 
increased risk of infections (1, 4, 5). Staphylococcus 
aureus is present in lesions of 20 to 50 percent of 
psoriatic patients. Therefore, regional anesthesia or 
intravenous cannulae should not be directed at these 
sites to prevent septicemia. Anesthesiologist must 
protect the skin in perioperative period. Tapes must be 
used in most necessary cases and intravenous catheters 
should be sutured in place or wrapped with web roll (1) 
Pruritus after administration of neuraxial opioids is an 
adverse effect with an incidence rate of 0-100%. It 
seems to be lower in epidural use of opioids versus 
spinal administration (1). Naloxone and propofol are 
effective in managing the opioid–induced pruritus (6). 
Due to chronic corticosteroid therapy in psoriatic 
patients stress dose of corticosteroids should be 
provided during the perioperative period (1). 
Antibiotic prophylaxis is recommended in psoriatic 
patients undergoing long procedures to prevent 
surgical site infections. Third generation cephalosporin 
agents are the drug of choice and should be 
administered 60 minutes prior to the skin incision. 
Additional intra-operative dose should be used for 
prolonged procedures and in case of significant blood 
loss during the surgery (1, 4, 5). Perioperative 
adjustment of disease modifying drugs must be done. 
Methotrexate must be continued preoperatively. 
Leflunomide should be discontinued at least 2 weeks 
prior to the surgery due to its association with 
increased perioperative infections. Based on current 
guidelines biologic agents should be discontinued 
based on their half-lives and should be restarted after 
the surgery and the removal of stitches that is usually 
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about two weeks later. Etanercept should be 
discontinued for 2 weeks, adalimumab for 3 to 4 weeks 
and infliximab for 6 to 8 weeks (4-6). Renal and liver 
function tests should be assessed when 
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